Welcome to the 2nd Annual Optimizing Safety Summit
With more than 300 trials in preclinical and clinical development actively using AAV as their vector of choice, the priority for any company working in this space is to ensure that each and every one of those therapies is the safest version it can be.
In this context, the 2nd Annual Optimizing AAV Safety Summit returned for 2023, which brought together aav-based therapy leaders across non-clinical development, clinical development, toxicology, biodistribution, and immunology who are all working to optimize the safety of their AAV-based drug products in their day-to-day.
By addressing key topics including how to extract the most relevant data from preclinical studies to better inform how humans will respond to an AAV-based therapy in the clinic, analyzing potential integration risks of AAV serotypes, and investigating regulatory approaches to safety packages for submission, this meeting informed your peers how to streamline AAV safety processes to de-risk delays and shorten timelines to approval.
Join us in Boston for 2024 to be part of the solution to bringing safer, effective aav therapies to patients and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development.
"Very informative and intellectually stimulating with engaged participants and high-quality speakers."
A past Optimizing AAV Safety Summit attendee, bridgebio
2023 World-Class Speaker Faculty Includes:
Previously Attending Companies
"This summit provided solid scientific discussion of emerging data and topics, as well as an opportunity to talk about the potential implications and considerations for clinical development programs."
A past Optimizing AAV Safety Summit attendee, BridgeBio